Cline: StemCART updates on achieved milestones on the way to phase 1 study
Cline Scientific AB (publ) ("Cline" or the "Company") last three experimental campaigns show successful results in measures of initial cell dose and important time aspects.
During the autumn, Cline, as previously communicated, carried out three major experimental campaigns in the StemCART project. These aimed to arrive at a suitable starting dose of chondrocyte cells to initiate a clear regeneration of the cartilage tissue. Cells grown according to Cline's method and matrix were placed within a controlled injury made in cartilage tissue removed from knee joints. The goal was to test various doses from a few tens of thousands to several million cells. The campaigns resulted in finding a suitable initial dose for cartilage regeneration for this type of injury. The extent of regeneration was analyzed on several occasions within 8 weeks and the desired regeneration result was achieved. These results consist of factors such as visible formation of tissues, gene expression and cell viability, among other. Thus, this milestone has been achieved.
As the next step, Cline is planning to combine cells and the matrix in 3D configuration before implantation. This is to simplify implantation as well as both streamline and shorten the process between cell cultivation and implantation.
"The results of the last year's work show that our original plan is relevant in that the set goals are achieved. We feel confident in continuing with our plan to move step by step towards a Phase I clinical trial." Hanne Evenbratt VP of R&D.